A double-blind, placebo controlled pharmacodynamic study of the effect of INCB013739 on systemic and adipose tissue 11betaHSD1 activity in obese, insulin resistant subjects.

Trial Profile

A double-blind, placebo controlled pharmacodynamic study of the effect of INCB013739 on systemic and adipose tissue 11betaHSD1 activity in obese, insulin resistant subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2011

At a glance

  • Drugs INCB 13739 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top